Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) Stock Competitors & Peer Comparison
See AKUMS.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AKUMS.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AKUMS.NS | ₹822.55 | +0.97% | 126.5B | 43.75 | ₹18.89 | +0.36% |
| SUNPHARMA.NS | ₹1,781.00 | -1.28% | 4.3T | 34.60 | ₹51.48 | +0.90% |
| SUNPHARMA.BO | ₹1,783.25 | -0.99% | 4.3T | 34.97 | ₹51.00 | +0.90% |
| DIVISLAB.BO | ₹9,580.00 | +0.37% | 2.6T | 86.94 | ₹110.19 | +0.31% |
| DIVISLAB.NS | ₹9,588.00 | +0.40% | 2.5T | 87.04 | ₹110.15 | +0.31% |
| TORNTPHARM.BO | ₹4,710.00 | -1.42% | 1.8T | 71.47 | ₹65.90 | +0.81% |
| TORNTPHARM.NS | ₹4,716.20 | -1.17% | 1.8T | 70.67 | ₹66.74 | +0.81% |
| ZYDUSLIFE.BO | ₹1,154.00 | -0.52% | 1.2T | 27.18 | ₹42.46 | +0.09% |
| ZYDUSLIFE.NS | ₹1,153.00 | -0.56% | 1.2T | 27.00 | ₹42.71 | +0.09% |
| LAURUSLABS.BO | ₹2,055.00 | +0.05% | 1.1T | 101.18 | ₹20.31 | +0.10% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
AKUMS.NS vs SUNPHARMA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUNPHARMA.NS trades at ₹1,781.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUNPHARMA.NS's P/E ratio is 34.60. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, AKUMS.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
AKUMS.NS vs SUNPHARMA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUNPHARMA.BO trades at ₹1,783.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUNPHARMA.BO's P/E ratio is 34.97. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, AKUMS.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
AKUMS.NS vs DIVISLAB.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, DIVISLAB.BO has a market cap of 2.6T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while DIVISLAB.BO trades at ₹9,580.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas DIVISLAB.BO's P/E ratio is 86.94. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, AKUMS.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check DIVISLAB.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
AKUMS.NS vs DIVISLAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, DIVISLAB.NS has a market cap of 2.5T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while DIVISLAB.NS trades at ₹9,588.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas DIVISLAB.NS's P/E ratio is 87.04. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, AKUMS.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check DIVISLAB.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
AKUMS.NS vs TORNTPHARM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, TORNTPHARM.BO has a market cap of 1.8T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while TORNTPHARM.BO trades at ₹4,710.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas TORNTPHARM.BO's P/E ratio is 71.47. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, AKUMS.NS is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check TORNTPHARM.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
AKUMS.NS vs TORNTPHARM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, TORNTPHARM.NS has a market cap of 1.8T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while TORNTPHARM.NS trades at ₹4,716.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas TORNTPHARM.NS's P/E ratio is 70.67. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, AKUMS.NS is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check TORNTPHARM.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
AKUMS.NS vs ZYDUSLIFE.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ZYDUSLIFE.BO has a market cap of 1.2T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ZYDUSLIFE.BO trades at ₹1,154.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ZYDUSLIFE.BO's P/E ratio is 27.18. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ZYDUSLIFE.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
AKUMS.NS vs ZYDUSLIFE.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ZYDUSLIFE.NS has a market cap of 1.2T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ZYDUSLIFE.NS trades at ₹1,153.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ZYDUSLIFE.NS's P/E ratio is 27.00. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ZYDUSLIFE.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
AKUMS.NS vs LAURUSLABS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, LAURUSLABS.BO has a market cap of 1.1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while LAURUSLABS.BO trades at ₹2,055.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas LAURUSLABS.BO's P/E ratio is 101.18. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check LAURUSLABS.BO's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
AKUMS.NS vs LAURUSLABS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, LAURUSLABS.NS has a market cap of 1.1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while LAURUSLABS.NS trades at ₹2,052.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas LAURUSLABS.NS's P/E ratio is 101.32. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check LAURUSLABS.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
AKUMS.NS vs CIPLA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while CIPLA.BO trades at ₹1,329.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas CIPLA.BO's P/E ratio is 31.88. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check CIPLA.BO's competition here
Cipla Limited (NSE: CIPLA.NS)
AKUMS.NS vs CIPLA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while CIPLA.NS trades at ₹1,327.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas CIPLA.NS's P/E ratio is 31.83. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check CIPLA.NS's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
AKUMS.NS vs MANKIND.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while MANKIND.NS trades at ₹2,500.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas MANKIND.NS's P/E ratio is 47.83. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check MANKIND.NS's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
AKUMS.NS vs MANKIND.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while MANKIND.BO trades at ₹2,494.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas MANKIND.BO's P/E ratio is 47.72. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check MANKIND.BO's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
AKUMS.NS vs DRREDDY.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while DRREDDY.BO trades at ₹1,202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas DRREDDY.BO's P/E ratio is 30.26. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, AKUMS.NS is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check DRREDDY.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
AKUMS.NS vs DRREDDY.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while DRREDDY.NS trades at ₹1,203.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas DRREDDY.NS's P/E ratio is 30.31. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, AKUMS.NS is less volatile compared to DRREDDY.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check DRREDDY.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
AKUMS.NS vs AUROPHARMA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AUROPHARMA.BO has a market cap of 969.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AUROPHARMA.BO trades at ₹1,685.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AUROPHARMA.BO's P/E ratio is 26.33. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check AUROPHARMA.BO's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
AKUMS.NS vs AUROPHARMA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AUROPHARMA.NS has a market cap of 967.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AUROPHARMA.NS trades at ₹1,682.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AUROPHARMA.NS's P/E ratio is 26.28. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check AUROPHARMA.NS's competition here
Lupin Limited (NSE: LUPIN.NS)
AKUMS.NS vs LUPIN.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, LUPIN.NS has a market cap of 920.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while LUPIN.NS trades at ₹2,012.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas LUPIN.NS's P/E ratio is 15.80. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, AKUMS.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check LUPIN.NS's competition here
Lupin Limited (BSE: LUPIN.BO)
AKUMS.NS vs LUPIN.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, LUPIN.BO has a market cap of 915.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while LUPIN.BO trades at ₹2,007.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas LUPIN.BO's P/E ratio is 15.75. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, AKUMS.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check LUPIN.BO's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
AKUMS.NS vs GLENMARK.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLENMARK.BO has a market cap of 660.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLENMARK.BO trades at ₹2,286.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLENMARK.BO's P/E ratio is 35.90. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLENMARK.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
AKUMS.NS vs GLENMARK.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLENMARK.NS has a market cap of 644.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLENMARK.NS trades at ₹2,282.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLENMARK.NS's P/E ratio is 37.41. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLENMARK.NS's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
AKUMS.NS vs ALKEM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ALKEM.BO has a market cap of 639.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ALKEM.BO trades at ₹5,360.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ALKEM.BO's P/E ratio is 29.70. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ALKEM.BO's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
AKUMS.NS vs ALKEM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ALKEM.NS has a market cap of 639.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ALKEM.NS trades at ₹5,350.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ALKEM.NS's P/E ratio is 29.62. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ALKEM.NS's competition here
Gland Pharma Limited (NSE: GLAND.NS)
AKUMS.NS vs GLAND.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLAND.NS has a market cap of 519.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLAND.NS trades at ₹3,150.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLAND.NS's P/E ratio is 45.95. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLAND.NS's competition here
Gland Pharma Limited (BSE: GLAND.BO)
AKUMS.NS vs GLAND.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLAND.BO has a market cap of 519.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLAND.BO trades at ₹3,151.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLAND.BO's P/E ratio is 45.99. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLAND.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLAND.BO's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
AKUMS.NS vs IPCALAB.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, IPCALAB.BO has a market cap of 495.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while IPCALAB.BO trades at ₹1,939.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas IPCALAB.BO's P/E ratio is 36.63. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check IPCALAB.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
AKUMS.NS vs IPCALAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, IPCALAB.NS has a market cap of 491.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while IPCALAB.NS trades at ₹1,938.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas IPCALAB.NS's P/E ratio is 36.41. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check IPCALAB.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
AKUMS.NS vs AJANTPHARM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AJANTPHARM.NS has a market cap of 446B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AJANTPHARM.NS trades at ₹3,569.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AJANTPHARM.NS's P/E ratio is 39.35. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, AKUMS.NS is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
AKUMS.NS vs AJANTPHARM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AJANTPHARM.BO has a market cap of 445.3B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AJANTPHARM.BO trades at ₹3,569.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AJANTPHARM.BO's P/E ratio is 39.34. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, AKUMS.NS is less volatile compared to AJANTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
AKUMS.NS vs SUVENPHAR.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUVENPHAR.NS's ROE of +0.03%. Regarding short-term risk, AKUMS.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
AKUMS.NS vs SUVENPHAR.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, AKUMS.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SUVENPHAR.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
AKUMS.NS vs EMCURE.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, EMCURE.NS has a market cap of 363.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while EMCURE.NS trades at ₹1,918.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas EMCURE.NS's P/E ratio is 35.06. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check EMCURE.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
AKUMS.NS vs NEULANDLAB.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NEULANDLAB.BO has a market cap of 278.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NEULANDLAB.BO trades at ₹21,665.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NEULANDLAB.BO's P/E ratio is 55.08. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, AKUMS.NS is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check NEULANDLAB.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
AKUMS.NS vs NEULANDLAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NEULANDLAB.NS has a market cap of 277.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NEULANDLAB.NS trades at ₹21,655.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NEULANDLAB.NS's P/E ratio is 54.90. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, AKUMS.NS is less volatile compared to NEULANDLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check NEULANDLAB.NS's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
AKUMS.NS vs PPLPHARMA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, PPLPHARMA.NS has a market cap of 268.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while PPLPHARMA.NS trades at ₹203.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas PPLPHARMA.NS's P/E ratio is -173.06. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, AKUMS.NS is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check PPLPHARMA.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
AKUMS.NS vs PPLPHARMA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, PPLPHARMA.BO has a market cap of 268.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while PPLPHARMA.BO trades at ₹202.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas PPLPHARMA.BO's P/E ratio is -173.12. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, AKUMS.NS is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check PPLPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
AKUMS.NS vs PEL.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, AKUMS.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check PEL.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
AKUMS.NS vs GRANULES.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GRANULES.BO has a market cap of 210.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GRANULES.BO trades at ₹845.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GRANULES.BO's P/E ratio is 32.32. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, AKUMS.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GRANULES.BO's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
AKUMS.NS vs SHILPAMED.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SHILPAMED.NS has a market cap of 209.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SHILPAMED.NS trades at ₹1,071.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SHILPAMED.NS's P/E ratio is 68.06. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SHILPAMED.NS's competition here
Granules India Limited (NSE: GRANULES.NS)
AKUMS.NS vs GRANULES.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GRANULES.NS has a market cap of 209.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GRANULES.NS trades at ₹845.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GRANULES.NS's P/E ratio is 32.12. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, AKUMS.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GRANULES.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
AKUMS.NS vs CAPLIPOINT.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, CAPLIPOINT.BO has a market cap of 201.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while CAPLIPOINT.BO trades at ₹2,650.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas CAPLIPOINT.BO's P/E ratio is 31.15. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check CAPLIPOINT.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
AKUMS.NS vs CAPLIPOINT.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, CAPLIPOINT.NS has a market cap of 201.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while CAPLIPOINT.NS trades at ₹2,649.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas CAPLIPOINT.NS's P/E ratio is 31.13. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check CAPLIPOINT.NS's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
AKUMS.NS vs COHANCE.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, COHANCE.NS has a market cap of 174.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while COHANCE.NS trades at ₹455.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas COHANCE.NS's P/E ratio is 137.73. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, AKUMS.NS is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check COHANCE.NS's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
AKUMS.NS vs COHANCE.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, COHANCE.BO has a market cap of 173.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while COHANCE.BO trades at ₹455.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas COHANCE.BO's P/E ratio is 143.81. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, AKUMS.NS is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check COHANCE.BO's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
AKUMS.NS vs ALIVUS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ALIVUS.BO has a market cap of 168.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ALIVUS.BO trades at ₹1,370.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ALIVUS.BO's P/E ratio is 27.88. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ALIVUS.BO's competition here
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS)
AKUMS.NS vs ALIVUS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ALIVUS.NS has a market cap of 168.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ALIVUS.NS trades at ₹1,370.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ALIVUS.NS's P/E ratio is 27.16. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check ALIVUS.NS's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
AKUMS.NS vs APLLTD.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, APLLTD.NS has a market cap of 163.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while APLLTD.NS trades at ₹833.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas APLLTD.NS's P/E ratio is 21.83. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check APLLTD.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
AKUMS.NS vs APLLTD.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, APLLTD.BO has a market cap of 163.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while APLLTD.BO trades at ₹833.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas APLLTD.BO's P/E ratio is 21.81. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check APLLTD.BO's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
AKUMS.NS vs ERIS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ERIS.BO has a market cap of 159B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ERIS.BO trades at ₹1,146.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ERIS.BO's P/E ratio is 37.19. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ERIS.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
AKUMS.NS vs ERIS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ERIS.NS has a market cap of 158.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ERIS.NS trades at ₹1,145.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ERIS.NS's P/E ratio is 32.41. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to ERIS.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ERIS.NS's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
AKUMS.NS vs JUBLPHARMA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, JUBLPHARMA.BO has a market cap of 154.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while JUBLPHARMA.BO trades at ₹974.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas JUBLPHARMA.BO's P/E ratio is 40.43. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, AKUMS.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check JUBLPHARMA.BO's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
AKUMS.NS vs JUBLPHARMA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, JUBLPHARMA.NS has a market cap of 154.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while JUBLPHARMA.NS trades at ₹974.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas JUBLPHARMA.NS's P/E ratio is 40.39. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, AKUMS.NS is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check JUBLPHARMA.NS's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
AKUMS.NS vs ASTRAZEN.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ASTRAZEN.NS has a market cap of 148.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ASTRAZEN.NS trades at ₹5,918.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ASTRAZEN.NS's P/E ratio is 87.36. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, AKUMS.NS is less volatile compared to ASTRAZEN.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ASTRAZEN.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
AKUMS.NS vs ASTRAZEN.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ASTRAZEN.BO has a market cap of 148B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ASTRAZEN.BO trades at ₹5,918.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ASTRAZEN.BO's P/E ratio is 87.23. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, AKUMS.NS is less volatile compared to ASTRAZEN.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ASTRAZEN.BO's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
AKUMS.NS vs NATCOPHARM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NATCOPHARM.NS has a market cap of 145.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NATCOPHARM.NS trades at ₹810.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NATCOPHARM.NS's P/E ratio is 13.36. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
AKUMS.NS vs NATCOPHARM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NATCOPHARM.BO has a market cap of 145.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NATCOPHARM.BO trades at ₹810.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NATCOPHARM.BO's P/E ratio is 13.37. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check NATCOPHARM.BO's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
AKUMS.NS vs GLS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
AKUMS.NS vs GLS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GLS.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
AKUMS.NS vs SUDEEPPHRM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUDEEPPHRM.NS has a market cap of 132.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUDEEPPHRM.NS trades at ₹1,170.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUDEEPPHRM.NS's P/E ratio is 72.38. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, AKUMS.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SUDEEPPHRM.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
AKUMS.NS vs CAPPL.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to CAPPL.BO's ROE of +0.05%. Regarding short-term risk, AKUMS.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check CAPPL.BO's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
AKUMS.NS vs VIYASH.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, VIYASH.NS has a market cap of 105.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while VIYASH.NS trades at ₹240.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas VIYASH.NS's P/E ratio is 57.88. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, AKUMS.NS is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check VIYASH.NS's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
AKUMS.NS vs SHILPAMED.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SHILPAMED.BO has a market cap of 104.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SHILPAMED.BO trades at ₹1,072.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SHILPAMED.BO's P/E ratio is 70.35. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SHILPAMED.BO's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
AKUMS.NS vs STAR.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, STAR.NS has a market cap of 101.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while STAR.NS trades at ₹1,100.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas STAR.NS's P/E ratio is 16.55. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, AKUMS.NS is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
AKUMS.NS vs STAR.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, STAR.BO has a market cap of 101.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while STAR.BO trades at ₹1,100.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas STAR.BO's P/E ratio is 16.54. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, AKUMS.NS is less volatile compared to STAR.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check STAR.BO's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
AKUMS.NS vs PGHL.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, PGHL.BO has a market cap of 87B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while PGHL.BO trades at ₹5,232.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas PGHL.BO's P/E ratio is 24.34. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to PGHL.BO's ROE of +0.62%. Regarding short-term risk, AKUMS.NS is less volatile compared to PGHL.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check PGHL.BO's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
AKUMS.NS vs PGHL.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, PGHL.NS has a market cap of 86.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while PGHL.NS trades at ₹5,234.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas PGHL.NS's P/E ratio is 24.35. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to PGHL.NS's ROE of +0.62%. Regarding short-term risk, AKUMS.NS is less volatile compared to PGHL.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check PGHL.NS's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
AKUMS.NS vs AARTIPHARM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AARTIPHARM.NS has a market cap of 86.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AARTIPHARM.NS trades at ₹953.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AARTIPHARM.NS's P/E ratio is 40.55. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
AKUMS.NS vs AARTIPHARM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AARTIPHARM.BO has a market cap of 86B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AARTIPHARM.BO trades at ₹953.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AARTIPHARM.BO's P/E ratio is 40.55. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, AKUMS.NS is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AARTIPHARM.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
AKUMS.NS vs MOREPENLAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, MOREPENLAB.NS has a market cap of 80.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while MOREPENLAB.NS trades at ₹146.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas MOREPENLAB.NS's P/E ratio is 57.31. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check MOREPENLAB.NS's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
AKUMS.NS vs MOREPENLAB.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, MOREPENLAB.BO has a market cap of 80.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while MOREPENLAB.BO trades at ₹146.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas MOREPENLAB.BO's P/E ratio is 84.86. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check MOREPENLAB.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
AKUMS.NS vs BLISSGVS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, BLISSGVS.NS has a market cap of 72.3B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while BLISSGVS.NS trades at ₹681.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas BLISSGVS.NS's P/E ratio is 52.94. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
AKUMS.NS vs BLISSGVS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, BLISSGVS.BO has a market cap of 72.3B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while BLISSGVS.BO trades at ₹677.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas BLISSGVS.BO's P/E ratio is 52.67. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check BLISSGVS.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
AKUMS.NS vs SUVEN.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUVEN.NS has a market cap of 69.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUVEN.NS trades at ₹305.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUVEN.NS's P/E ratio is -21.51. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SUVEN.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
AKUMS.NS vs SUVEN.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SUVEN.BO has a market cap of 68.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SUVEN.BO trades at ₹305.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SUVEN.BO's P/E ratio is -24.64. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SUVEN.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
AKUMS.NS vs INNOVACAP.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, INNOVACAP.NS has a market cap of 66.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while INNOVACAP.NS trades at ₹1,166.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas INNOVACAP.NS's P/E ratio is 54.83. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, AKUMS.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check INNOVACAP.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
AKUMS.NS vs IOLCP.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, IOLCP.BO has a market cap of 64.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while IOLCP.BO trades at ₹220.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas IOLCP.BO's P/E ratio is 36.13. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to IOLCP.BO's ROE of +0.09%. Regarding short-term risk, AKUMS.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check IOLCP.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
AKUMS.NS vs IOLCP.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, IOLCP.NS has a market cap of 64.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while IOLCP.NS trades at ₹220.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas IOLCP.NS's P/E ratio is 35.98. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to IOLCP.NS's ROE of +0.09%. Regarding short-term risk, AKUMS.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check IOLCP.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
AKUMS.NS vs SPARC.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SPARC.BO has a market cap of 64B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SPARC.BO trades at ₹197.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SPARC.BO's P/E ratio is 4.13. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SPARC.BO's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
AKUMS.NS vs SPARC.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SPARC.NS has a market cap of 63.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SPARC.NS trades at ₹196.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, AKUMS.NS is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SPARC.NS's competition here
FDC Limited (NSE: FDC.NS)
AKUMS.NS vs FDC.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, FDC.NS has a market cap of 53.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while FDC.NS trades at ₹328.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas FDC.NS's P/E ratio is 19.00. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check FDC.NS's competition here
FDC Limited (BSE: FDC.BO)
AKUMS.NS vs FDC.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, FDC.BO has a market cap of 53.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while FDC.BO trades at ₹328.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas FDC.BO's P/E ratio is 19.01. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to FDC.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check FDC.BO's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
AKUMS.NS vs ORCHPHARMA.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ORCHPHARMA.BO has a market cap of 52B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ORCHPHARMA.BO trades at ₹1,025.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ORCHPHARMA.BO's P/E ratio is 79.89. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, AKUMS.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ORCHPHARMA.BO's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
AKUMS.NS vs ORCHPHARMA.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, ORCHPHARMA.NS has a market cap of 51.9B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while ORCHPHARMA.NS trades at ₹1,023.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas ORCHPHARMA.NS's P/E ratio is 165.15. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AKUMS.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check ORCHPHARMA.NS's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
AKUMS.NS vs SEQUENT.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SEQUENT.NS's ROE of +0.08%. Regarding short-term risk, AKUMS.NS is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SEQUENT.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
AKUMS.NS vs SEQUENT.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to SEQUENT.BO's ROE of +0.08%. Regarding short-term risk, AKUMS.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check SEQUENT.BO's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
AKUMS.NS vs NOVARTIND.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NOVARTIND.BO has a market cap of 49.7B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NOVARTIND.BO trades at ₹2,011.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NOVARTIND.BO's P/E ratio is 52.34. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
AKUMS.NS vs NOVARTIND.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, NOVARTIND.NS has a market cap of 49.6B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while NOVARTIND.NS trades at ₹2,010.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas NOVARTIND.NS's P/E ratio is 52.31. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check NOVARTIND.NS's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
AKUMS.NS vs RPGLIFE.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, RPGLIFE.BO has a market cap of 48.3B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while RPGLIFE.BO trades at ₹2,897.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas RPGLIFE.BO's P/E ratio is 41.61. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
AKUMS.NS vs RPGLIFE.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, RPGLIFE.NS has a market cap of 47.8B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while RPGLIFE.NS trades at ₹2,892.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas RPGLIFE.NS's P/E ratio is 41.54. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, AKUMS.NS is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check RPGLIFE.NS's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
AKUMS.NS vs GUFICBIO.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GUFICBIO.NS has a market cap of 42.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GUFICBIO.NS trades at ₹422.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GUFICBIO.NS's P/E ratio is 57.69. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, AKUMS.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
AKUMS.NS vs GUFICBIO.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GUFICBIO.BO has a market cap of 42.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GUFICBIO.BO trades at ₹422.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GUFICBIO.BO's P/E ratio is 57.71. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, AKUMS.NS is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for AKUMS.NS.Check GUFICBIO.BO's competition here
Gujarat Themis Biosyn Limited (BSE: GUJTHEM.BO)
AKUMS.NS vs GUJTHEM.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GUJTHEM.BO has a market cap of 41.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GUJTHEM.BO trades at ₹379.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GUJTHEM.BO's P/E ratio is 84.96. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, AKUMS.NS is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GUJTHEM.BO's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
AKUMS.NS vs GUJTHEM.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, GUJTHEM.NS has a market cap of 41.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while GUJTHEM.NS trades at ₹379.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas GUJTHEM.NS's P/E ratio is 88.26. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, AKUMS.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check GUJTHEM.NS's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
AKUMS.NS vs UNICHEMLAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, UNICHEMLAB.NS has a market cap of 38.5B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while UNICHEMLAB.NS trades at ₹546.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas UNICHEMLAB.NS's P/E ratio is 12.62. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check UNICHEMLAB.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
AKUMS.NS vs UNICHEMLAB.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, UNICHEMLAB.BO has a market cap of 38.4B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while UNICHEMLAB.BO trades at ₹545.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas UNICHEMLAB.BO's P/E ratio is 12.60. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, AKUMS.NS is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check UNICHEMLAB.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
AKUMS.NS vs AARTIDRUGS.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AARTIDRUGS.NS has a market cap of 38.2B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AARTIDRUGS.NS trades at ₹417.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AARTIDRUGS.NS's P/E ratio is 19.69. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AARTIDRUGS.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
AKUMS.NS vs AARTIDRUGS.BO Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, AARTIDRUGS.BO has a market cap of 38.1B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while AARTIDRUGS.BO trades at ₹416.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas AARTIDRUGS.BO's P/E ratio is 19.61. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, AKUMS.NS is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check AARTIDRUGS.BO's competition here
Ind-Swift Laboratories Limited (NSE: INDSWFTLAB.NS)
AKUMS.NS vs INDSWFTLAB.NS Comparison October 2026
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKUMS.NS stands at 126.5B. In comparison, INDSWFTLAB.NS has a market cap of 34B. Regarding current trading prices, AKUMS.NS is priced at ₹822.55 on the NSE, while INDSWFTLAB.NS trades at ₹391.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKUMS.NS currently has a P/E ratio of 43.75, whereas INDSWFTLAB.NS's P/E ratio is 57.34. In terms of profitability, AKUMS.NS's ROE is +0.09%, compared to INDSWFTLAB.NS's ROE of +0.04%. Regarding short-term risk, AKUMS.NS is less volatile compared to INDSWFTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AKUMS.NS.Check INDSWFTLAB.NS's competition here